Intellia Therapeutics (NASDAQ:NTLA) Now Covered by Analysts at Roth Capital

Equities research analysts at Roth Capital initiated coverage on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report issued on Monday, Marketbeat.com reports. The brokerage set a “neutral” rating and a $16.00 price target on the stock. Roth Capital’s target price points to a potential upside of 15.03% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Chardan Capital restated a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a research report on Wednesday, February 27th. BidaskClub upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. Wedbush upgraded shares of Intellia Therapeutics from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $20.00 to $21.00 in a research report on Friday, May 3rd. Evercore ISI started coverage on shares of Intellia Therapeutics in a research report on Thursday, April 11th. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research lowered shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company’s stock. Intellia Therapeutics has an average rating of “Hold” and an average target price of $27.36.

Intellia Therapeutics stock opened at $13.91 on Monday. The company has a current ratio of 7.74, a quick ratio of 7.74 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $635.84 million, a price-to-earnings ratio of -7.03 and a beta of 2.57. Intellia Therapeutics has a 1 year low of $11.03 and a 1 year high of $32.95.



Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.04. The firm had revenue of $10.43 million for the quarter, compared to analyst estimates of $9.43 million. Intellia Therapeutics had a negative net margin of 257.28% and a negative return on equity of 31.68%. The firm’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.51) earnings per share. Sell-side analysts predict that Intellia Therapeutics will post -2.49 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of NTLA. Ameritas Investment Corp acquired a new stake in shares of Intellia Therapeutics in the first quarter valued at $28,000. Tortoise Investment Management LLC grew its stake in shares of Intellia Therapeutics by 100.0% in the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock valued at $34,000 after buying an additional 1,000 shares in the last quarter. Quantamental Technologies LLC grew its stake in shares of Intellia Therapeutics by 1,170.4% in the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock valued at $56,000 after buying an additional 3,043 shares in the last quarter. Nikko Asset Management Americas Inc. grew its stake in shares of Intellia Therapeutics by 20.0% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 5,980 shares of the company’s stock valued at $82,000 after buying an additional 995 shares in the last quarter. Finally, Resources Investment Advisors Inc. acquired a new stake in shares of Intellia Therapeutics in the first quarter valued at $92,000. Hedge funds and other institutional investors own 74.34% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Featured Story: What is a conference call?

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.